ArticleNature neuroscience2022
Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties.
Abstract read
In one paragraph
Article in Nature neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of dopamine partial agonist antipsychotics on suicide risk in persons with schizophrenia and schizoaffective disorders: A systematic review and meta-analysis.Schizophrenia research · 2026Pooled it
- Structure-based design of subtype-selective psychedelic analogs.Nature communications · 2026Article
- The structure of the dopamine DScience advances · 2026Article
- A structural overview of G-protein-coupled receptors in neurological disorders.Acta pharmacologica Sinica · 2026Review
- Benchmarking pJournal of chemical information and modeling · 2026Article
- Computational design of constitutively active mutants of Dopamine D2 receptor inspired by ligand-independent activation mechanisms.BMC biology · 2026Article
- An isoflavone-enriched diet alleviates Parkinson's disease in mice by inhibiting ferroptosis through gut microbiota-mediated serotonin production.Frontiers in immunology · 2026Article
- Partial agonist antipsychotic drugs differentially interact with a secondary binding site at the dopamine D2 receptor.The international journal of neuropsychopharmacology · 2025Article
- Discovery and proof-of-concept study of a novel highly selective sigma-1 receptor agonist for antipsychotic drug development.Acta pharmaceutica Sinica. B · 2025Article
- Structural Aspects of Arylpiperazines as Aminergic GPCR Ligands.Molecules (Basel, Switzerland) · 2025Review
- Molecular insights into the modulation of the 5HTFEBS letters · 2025Article
- Exploring the Potential of Coumarin Derivatives on Serotonin Receptors 5-HTInternational journal of molecular sciences · 2025Article
- Molecular simulations reveal intricate coupling between agonist-bound β-adrenergic receptors and G protein.iScience · 2025Article
- The impact of opioid analgesics with concomitant antipsychotic use on pain modulation and management in internal medicine: a cross-sequential study protocol.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- Molecular Dynamics (MD) Simulations Provide Insights into the Activation Mechanisms of 5-HTMolecules (Basel, Switzerland) · 2024Article
- Uncovering the unique characteristics of different groups of 5-HTPharmacological reports : PR · 2024Article
- Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HTMolecular psychiatry · 2024Article
- Article
- G Protein-Coupled Receptor-Ligand Pose and Functional Class Prediction.International journal of molecular sciences · 2024Article
- Unraveling the Mechanisms of Cannabidiol's Pharmacological Actions: A Comprehensive Research Overview.Topics in current chemistry (Cham) · 2024Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors.
Zhangcheng Chen *State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Luyu Fan *State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Huan Wang *iHuman Institute, ShanghaiTech University, Shanghai, China.
Jing Yu *State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Dengyu Lu *Institute of Neuroscience, State Key Laboratory of Neuroscience, CAS Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technolog, Chinese Academy of Sciences, Shanghai, China.
Jianzhong QiState Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Fen NieState Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Zhipu LuoInstitute of Molecular Enzymology, Soochow University, Suzhou, China.
Zhen LiuInstitute of Neuroscience, State Key Laboratory of Neuroscience, CAS Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technolog, Chinese Academy of Sciences, Shanghai, China.
Jianjun ChengiHuman Institute, ShanghaiTech University, Shanghai, China. chengjj@shanghaitech.edu.cn.ORCID http://orcid.org/0000-0001-6065-2682
Sheng WangState Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China. wangsheng@sibcb.ac.cn.ORCID http://orcid.org/0000-0003-4176-8844
Funding
No grant is acknowledged in the PubMed record.
Abstract
Partial agonist activity at the dopamine D
Indexed as
Antipsychotic AgentsAnimalsAntidepressive AgentsAripiprazoleMiceSerotoninAntidepressive AgentsAntipsychotic AgentsAripiprazoleSerotonin
Identifiers
PMID
34887590What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.